Tiziana Life Sciences shares are trading higher after the company announced the withdrawal of its proposed public offering.

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer | TLSA Stock News

Tiziana Life Sciences announced that its CEO, Ivor Elrifi, purchased 163,400 shares of the company's stock, increasing his total to 357,848 shares. Tiziana is a biotechnology firm developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for treating neuroinflammatory diseases. The company is conducting clinical trials for this innovative therapy, which has shown promising results in patients with non-active secondary progressive multiple sclerosis.

Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4% - Here's Why

Tiziana Life Sciences (NASDAQ:TLSA) shares fell 4.4% to $1.72, with trading volume down 42% from the average. Weiss Ratings reiterated a "sell" rating, and the stock has a consensus "sell" rating. Institutional investors have adjusted their stakes, with some increasing and others reducing their holdings. Tiziana focuses on developing treatments for diseases in oncology and immunology. Despite the current "sell" rating, analysts suggest other stocks as better investments.

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial | TLSA Stock News

Tiziana Life Sciences is set to dose the first patient in its Phase 2 Alzheimer's trial next week. The trial will evaluate intranasal foralumab, both as monotherapy and in combination with anti-amyloid therapies, lecanemab or donanemab. The study aims to address neuroinflammation in Alzheimer's patients, potentially offering a new treatment paradigm. Baseline assessments and imaging have been completed, and the trial will focus on safety, efficacy, and cognitive function improvements.

Tiziana Life Sciences to Spin Out IL-6 Asset into Separate Public Company

Tiziana Life Sciences Ltd. plans to spin out its anti-IL-6 receptor monoclonal antibody, TZLS-501, into a separate public company to enhance strategic focus and unlock shareholder value. Shareholders will receive shares in the new entity, pending approval and listing requirements. This follows increased interest in IL-6 therapeutics, highlighted by Novartis' $1.4 billion acquisition of Tourmaline Bio.